(ALB) Albemarle - Ratings and Ratios
Lithium, Bromine, Catalysts, Chemicals, Energy Storage
ALB EPS (Earnings per Share)
ALB Revenue
Description: ALB Albemarle
Albemarle Corporation is a leading global provider of energy storage solutions, operating through three main segments: Energy Storage, Specialties, and Ketjen. The companys Energy Storage segment is a key player in the lithium-ion battery market, supplying lithium compounds to various industries, including consumer electronics, electric vehicles, and renewable energy.
From a business perspective, Albemarles diversified product portfolio and customer base across multiple industries, such as energy, mobility, and health, position the company for long-term growth. The increasing demand for lithium-ion batteries, driven by the transition to electric vehicles and renewable energy, is a significant tailwind for the companys Energy Storage segment. Key Performance Indicators (KPIs) to watch include revenue growth, lithium production volumes, and average selling prices.
Albemarles Specialties segment is also noteworthy, with a strong presence in the bromine and lithium specialties markets. The companys expertise in producing high-quality, specialized chemicals for various applications, such as fire safety compounds and pharmaceuticals, is a competitive advantage. The Ketjen segment, with its focus on clean fuels technologies and performance catalyst solutions, is another important contributor to the companys overall performance.
From a financial perspective, Albemarles market capitalization and forward P/E ratio suggest that the company is expected to deliver earnings growth in the future. Key metrics to monitor include Return on Equity (ROE), which has been negative in recent times, and the companys ability to generate cash flow from operations. With a strong presence in the specialty chemicals industry and a diversified product portfolio, Albemarle is well-positioned to capitalize on emerging trends and drive long-term value creation.
Some additional KPIs that could be relevant for Albemarle include: Debt-to-Equity ratio, Interest Coverage ratio, and the companys capacity utilization rates in its various business segments. Monitoring these metrics can provide insights into the companys financial health, operational efficiency, and ability to invest in growth initiatives.
ALB Stock Overview
| Market Cap in USD | 8,629m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | 1994-02-17 |
ALB Stock Ratings
| Growth Rating | -69.4% |
| Fundamental | 12.4% |
| Dividend Rating | 56.2% |
| Return 12m vs S&P 500 | -28.6% |
| Analyst Rating | 3.43 of 5 |
ALB Dividends
| Dividend Yield 12m | 2.62% |
| Yield on Cost 5y | 2.18% |
| Annual Growth 5y | 0.89% |
| Payout Consistency | 97.2% |
| Payout Ratio | 58.0% |
ALB Growth Ratios
| Growth Correlation 3m | 76% |
| Growth Correlation 12m | -68.2% |
| Growth Correlation 5y | -56.2% |
| CAGR 5y | -35.49% |
| CAGR/Max DD 3y | -0.42 |
| CAGR/Mean DD 3y | -0.57 |
| Sharpe Ratio 12m | -0.32 |
| Alpha | 0.07 |
| Beta | 0.456 |
| Volatility | 69.83% |
| Current Volume | 3592.5k |
| Average Volume 20d | 3539.5k |
| Stop Loss | 71.5 (-4.7%) |
| Signal | 0.28 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-929.5m TTM) > 0 and > 6% of Revenue (6% = 299.6m TTM) |
| FCFTA -0.06 (>2.0%) and ΔFCFTA -1.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 51.18% (prev 43.81%; Δ 7.37pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 775.1m > Net Income -929.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (117.7m) change vs 12m ago 0.12% (target <= -2.0% for YES) |
| Gross Margin 7.76% (prev -8.32%; Δ 16.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 27.99% (prev 40.56%; Δ -12.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.90 (EBITDA TTM -281.6m / Interest Expense TTM 191.4m) >= 6 (WARN >= 3) |
Altman Z'' 2.40
| (A) 0.15 = (Total Current Assets 4.51b - Total Current Liabilities 1.95b) / Total Assets 17.29b |
| (B) 0.31 = Retained Earnings (Balance) 5.37b / Total Assets 17.29b |
| (C) -0.05 = EBIT TTM -938.7m / Avg Total Assets 17.84b |
| (D) 0.74 = Book Value of Equity 5.00b / Total Liabilities 6.79b |
| Total Rating: 2.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 12.39
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -9.42% = -4.71 |
| 3. FCF Margin -19.70% = -7.39 |
| 4. Debt/Equity 0.35 = 2.44 |
| 5. Debt/Ebitda -12.87 = -2.50 |
| 6. ROIC - WACC -13.95% = -12.50 |
| 7. RoE -9.19% = -1.53 |
| 8. Rev. Trend -87.32% = -4.37 |
| 9. Rev. CAGR -15.18% = -2.50 |
| 10. EPS Trend -62.10% = -1.55 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ALB shares?
Over the past week, the price has changed by -5.32%, over one month by -7.07%, over three months by +16.07% and over the past year by -14.21%.
Is Albemarle a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALB is around 64.33 USD . This means that ALB is currently overvalued and has a potential downside of -14.28%.
Is ALB a buy, sell or hold?
- Strong Buy: 6
- Buy: 3
- Hold: 17
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the ALB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 86 | 14.6% |
| Analysts Target Price | 86 | 14.6% |
| ValueRay Target Price | 69.7 | -7.1% |
Last update: 2025-09-12 04:30
ALB Fundamental Data Overview
CCE Cash And Equivalents = 1.81b USD (last quarter)
P/E Forward = 60.9756
P/S = 1.728
P/B = 1.0778
P/EG = 3.8061
Beta = 1.652
Revenue TTM = 4.99b USD
EBIT TTM = -938.7m USD
EBITDA TTM = -281.6m USD
Long Term Debt = 3.18b USD (from longTermDebt, last quarter)
Short Term Debt = 444.9m USD (from shortTermDebt, last quarter)
Debt = 3.62b USD (Calculated: Short Term 444.9m + Long Term 3.18b)
Net Debt = 1.91b USD (from netDebt column, last quarter)
Enterprise Value = 10.44b USD (8.63b + Debt 3.62b - CCE 1.81b)
Interest Coverage Ratio = -4.90 (Ebit TTM -938.7m / Interest Expense TTM 191.4m)
FCF Yield = -9.42% (FCF TTM -983.7m / Enterprise Value 10.44b)
FCF Margin = -19.70% (FCF TTM -983.7m / Revenue TTM 4.99b)
Net Margin = -18.61% (Net Income TTM -929.5m / Revenue TTM 4.99b)
Gross Margin = 7.76% ((Revenue TTM 4.99b - Cost of Revenue TTM 4.61b) / Revenue TTM)
Tobins Q-Ratio = 2.09 (Enterprise Value 10.44b / Book Value Of Equity 5.00b)
Interest Expense / Debt = 1.38% (Interest Expense 49.9m / Debt 3.62b)
Taxrate = 21.0% (US default)
NOPAT = -938.7m (EBIT -938.7m, no tax applied on loss)
Current Ratio = 2.31 (Total Current Assets 4.51b / Total Current Liabilities 1.95b)
Debt / Equity = 0.35 (Debt 3.62b / last Quarter total Stockholder Equity 10.24b)
Debt / EBITDA = -12.87 (Net Debt 1.91b / EBITDA -281.6m)
Debt / FCF = -3.68 (Debt 3.62b / FCF TTM -983.7m)
Total Stockholder Equity = 10.12b (last 4 quarters mean)
RoA = -5.38% (Net Income -929.5m, Total Assets 17.29b )
RoE = -9.19% (Net Income TTM -929.5m / Total Stockholder Equity 10.12b)
RoCE = -7.06% (Ebit -938.7m / (Equity 10.12b + L.T.Debt 3.18b))
RoIC = -8.20% (NOPAT -938.7m / Invested Capital 11.44b)
WACC = 5.74% (E(8.63b)/V(12.25b) * Re(7.70%)) + (D(3.62b)/V(12.25b) * Rd(1.38%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -36.36 | Cagr: -0.02%
Discount Rate = 7.70% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -983.7m)
Revenue Correlation: -87.32 | Revenue CAGR: -15.18%
Rev Growth-of-Growth: -8.99
EPS Correlation: -62.10 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 246.6
Additional Sources for ALB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle